Choice of treatment: outcomes and treatment goals
Rather, physicians were limited to ?-blockers, reserpine, and clonidine; imperfect add-on choices for at least some of the treatments, where a diuretic would be far more usual and probably preferable. [...]although there is a well-established, essentially additive effect on blood pressure produced b...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2003-10, Vol.146 (4), p.565-567 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 567 |
|---|---|
| container_issue | 4 |
| container_start_page | 565 |
| container_title | The American heart journal |
| container_volume | 146 |
| creator | Temple, Robert J. |
| description | Rather, physicians were limited to ?-blockers, reserpine, and clonidine; imperfect add-on choices for at least some of the treatments, where a diuretic would be far more usual and probably preferable. [...]although there is a well-established, essentially additive effect on blood pressure produced by angiotensin-converting enzyme inhibitors (ACEIs) and diuretics, although all outcome studies of ACEIs in heart failure used those drugs in addition to diuretics, and although that combination (unlike ACEIs alone) has a similar effect on blood pressure in both black and nonblack patients, such a combination could not, for the most part, be used in ALLHAT. [...]despite the constrained follow-on therapy, there was no difference between chlorthalidone, amlodipine, and lisinopril for the primary study outcome (total coronary heart disease or nonfatal myocardial infarction), all-cause mortality, or combined coronary heart disease. |
| doi_str_mv | 10.1016/S0002-8703(03)00362-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71286773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870303003624</els_id><sourcerecordid>71286773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-a89e888c565eb72008187cfa8e606b87ab0a61e000479d043b5726d2c0dc93b13</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo7rr6E5SCIHqoTpo0Sb2ILH7Bggf1HNJ0VrtsG01awX9v6i4ueBECQ8Iz70weQg4pnFOg4uIJALJUSWCnwM4AmMhSvkXGFAqZCsn5Nhn_IiOyF8IiXkWmxC4ZUZ4LzkCMCZ2-udpi4uZJ59F0DbbdZeL6zroGQ2LaavOevDqzDPtkZx4LHqzrhLzc3jxP79PZ493D9HqWWqaKLjWqQKWUzUWOpcwAFFXSzo1CAaJU0pRgBMW4E5dFBZyVucxElVmobMFKyibkZJX77t1Hj6HTTR0sLpemRdcHLWn8i5Qsgsd_wIXrfRt30zQHnrNoZIjLV5T1LgSPc_3u68b4L01BD0b1j1E96NLDGYxqHvuO1ul92WC16VorjMDVCsAo47NGr4OtsbVY1R5tpytX_zPiG18cgp8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504530971</pqid></control><display><type>article</type><title>Choice of treatment: outcomes and treatment goals</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>Temple, Robert J.</creator><creatorcontrib>Temple, Robert J.</creatorcontrib><description>Rather, physicians were limited to ?-blockers, reserpine, and clonidine; imperfect add-on choices for at least some of the treatments, where a diuretic would be far more usual and probably preferable. [...]although there is a well-established, essentially additive effect on blood pressure produced by angiotensin-converting enzyme inhibitors (ACEIs) and diuretics, although all outcome studies of ACEIs in heart failure used those drugs in addition to diuretics, and although that combination (unlike ACEIs alone) has a similar effect on blood pressure in both black and nonblack patients, such a combination could not, for the most part, be used in ALLHAT. [...]despite the constrained follow-on therapy, there was no difference between chlorthalidone, amlodipine, and lisinopril for the primary study outcome (total coronary heart disease or nonfatal myocardial infarction), all-cause mortality, or combined coronary heart disease.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/S0002-8703(03)00362-4</identifier><identifier>PMID: 14564306</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Angiotensin Receptor Antagonists ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - therapeutic use ; Benzimidazoles - administration & dosage ; Benzimidazoles - therapeutic use ; Blood pressure ; Blood Pressure - drug effects ; Cardiovascular disease ; Clinical Trials as Topic ; Drug Approval ; Drug therapy ; Heart attacks ; Losartan - administration & dosage ; Losartan - therapeutic use ; Tetrazoles - administration & dosage ; Tetrazoles - therapeutic use ; United States ; United States Food and Drug Administration</subject><ispartof>The American heart journal, 2003-10, Vol.146 (4), p.565-567</ispartof><rights>2003 Mosby, Inc.</rights><rights>Copyright Elsevier Limited Oct 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-a89e888c565eb72008187cfa8e606b87ab0a61e000479d043b5726d2c0dc93b13</citedby><cites>FETCH-LOGICAL-c389t-a89e888c565eb72008187cfa8e606b87ab0a61e000479d043b5726d2c0dc93b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1504530971?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14564306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Temple, Robert J.</creatorcontrib><title>Choice of treatment: outcomes and treatment goals</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Rather, physicians were limited to ?-blockers, reserpine, and clonidine; imperfect add-on choices for at least some of the treatments, where a diuretic would be far more usual and probably preferable. [...]although there is a well-established, essentially additive effect on blood pressure produced by angiotensin-converting enzyme inhibitors (ACEIs) and diuretics, although all outcome studies of ACEIs in heart failure used those drugs in addition to diuretics, and although that combination (unlike ACEIs alone) has a similar effect on blood pressure in both black and nonblack patients, such a combination could not, for the most part, be used in ALLHAT. [...]despite the constrained follow-on therapy, there was no difference between chlorthalidone, amlodipine, and lisinopril for the primary study outcome (total coronary heart disease or nonfatal myocardial infarction), all-cause mortality, or combined coronary heart disease.</description><subject>Angiotensin Receptor Antagonists</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular disease</subject><subject>Clinical Trials as Topic</subject><subject>Drug Approval</subject><subject>Drug therapy</subject><subject>Heart attacks</subject><subject>Losartan - administration & dosage</subject><subject>Losartan - therapeutic use</subject><subject>Tetrazoles - administration & dosage</subject><subject>Tetrazoles - therapeutic use</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1LxDAQhoMo7rr6E5SCIHqoTpo0Sb2ILH7Bggf1HNJ0VrtsG01awX9v6i4ueBECQ8Iz70weQg4pnFOg4uIJALJUSWCnwM4AmMhSvkXGFAqZCsn5Nhn_IiOyF8IiXkWmxC4ZUZ4LzkCMCZ2-udpi4uZJ59F0DbbdZeL6zroGQ2LaavOevDqzDPtkZx4LHqzrhLzc3jxP79PZ493D9HqWWqaKLjWqQKWUzUWOpcwAFFXSzo1CAaJU0pRgBMW4E5dFBZyVucxElVmobMFKyibkZJX77t1Hj6HTTR0sLpemRdcHLWn8i5Qsgsd_wIXrfRt30zQHnrNoZIjLV5T1LgSPc_3u68b4L01BD0b1j1E96NLDGYxqHvuO1ul92WC16VorjMDVCsAo47NGr4OtsbVY1R5tpytX_zPiG18cgp8</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>Temple, Robert J.</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20031001</creationdate><title>Choice of treatment: outcomes and treatment goals</title><author>Temple, Robert J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-a89e888c565eb72008187cfa8e606b87ab0a61e000479d043b5726d2c0dc93b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Angiotensin Receptor Antagonists</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular disease</topic><topic>Clinical Trials as Topic</topic><topic>Drug Approval</topic><topic>Drug therapy</topic><topic>Heart attacks</topic><topic>Losartan - administration & dosage</topic><topic>Losartan - therapeutic use</topic><topic>Tetrazoles - administration & dosage</topic><topic>Tetrazoles - therapeutic use</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Temple, Robert J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Temple, Robert J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Choice of treatment: outcomes and treatment goals</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>146</volume><issue>4</issue><spage>565</spage><epage>567</epage><pages>565-567</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Rather, physicians were limited to ?-blockers, reserpine, and clonidine; imperfect add-on choices for at least some of the treatments, where a diuretic would be far more usual and probably preferable. [...]although there is a well-established, essentially additive effect on blood pressure produced by angiotensin-converting enzyme inhibitors (ACEIs) and diuretics, although all outcome studies of ACEIs in heart failure used those drugs in addition to diuretics, and although that combination (unlike ACEIs alone) has a similar effect on blood pressure in both black and nonblack patients, such a combination could not, for the most part, be used in ALLHAT. [...]despite the constrained follow-on therapy, there was no difference between chlorthalidone, amlodipine, and lisinopril for the primary study outcome (total coronary heart disease or nonfatal myocardial infarction), all-cause mortality, or combined coronary heart disease.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>14564306</pmid><doi>10.1016/S0002-8703(03)00362-4</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2003-10, Vol.146 (4), p.565-567 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71286773 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; ProQuest Central UK/Ireland |
| subjects | Angiotensin Receptor Antagonists Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use Benzimidazoles - administration & dosage Benzimidazoles - therapeutic use Blood pressure Blood Pressure - drug effects Cardiovascular disease Clinical Trials as Topic Drug Approval Drug therapy Heart attacks Losartan - administration & dosage Losartan - therapeutic use Tetrazoles - administration & dosage Tetrazoles - therapeutic use United States United States Food and Drug Administration |
| title | Choice of treatment: outcomes and treatment goals |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T14%3A22%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Choice%20of%20treatment:%20outcomes%20and%20treatment%20goals&rft.jtitle=The%20American%20heart%20journal&rft.au=Temple,%20Robert%20J.&rft.date=2003-10-01&rft.volume=146&rft.issue=4&rft.spage=565&rft.epage=567&rft.pages=565-567&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/S0002-8703(03)00362-4&rft_dat=%3Cproquest_cross%3E71286773%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504530971&rft_id=info:pmid/14564306&rft_els_id=S0002870303003624&rfr_iscdi=true |